Vizsgálati helyszín
Nashville
Nashville, Tennessee 37203, Egyesült ÁllamokMég nincs intézményhez kötve
- 15futó vizsgálat
- 8lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 23 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis11 vizsgálat
- 3. fázis5 vizsgálat
- 1. fázis3 vizsgálat
- 1/2. fázis3 vizsgálat
- Állapot
- Toboroz9 vizsgálat
- Lezárult8 vizsgálat
- Fut, nem toboroz6 vizsgálat
- Fő szponzor
- GlaxoSmithKline18 vizsgálat
- Tesaro, Inc.4 vizsgálat
- ViiV Healthcare1 vizsgálat
Futó vizsgálatok
Toboroz
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
NCT07224672· 2. fázis· GlaxoSmithKline· Forrás
Contact: Phyu Naing (principal investigator)
Toboroz
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311· 2. fázis· GlaxoSmithKline· Forrás
Contact: Jesus Berdeja (principal investigator)
Toboroz
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
NCT07519395· 2. fázis· GlaxoSmithKline· Forrás
Contact: Stephanie Pointer (principal investigator)
Toboroz
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
NCT07277270· 1. fázis· GlaxoSmithKline· Forrás
Contact: Benjamin Garmezy (principal investigator)
Toboroz
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT07213609· 1/2. fázis· GlaxoSmithKline· Forrás
Contact: Deepak Bhamidipati (principal investigator)
Toboroz
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT06990880· 1/2. fázis· GlaxoSmithKline· Forrás
Contact: Benjamin Garmezy (principal investigator)
Toboroz
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
NCT06517875· 2. fázis· GlaxoSmithKline· Forrás
Contact: Jonathan Abbas (principal investigator)
Fut, nem toboroz
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· 3. fázis· GlaxoSmithKline· Forrás
Contact: Joseph Merriman (principal investigator)
Fut, nem toboroz
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
NCT05996471· 2. fázis· ViiV Healthcare· Forrás
Toboroz
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
NCT05714839· 1/2. fázis· GlaxoSmithKline· Forrás
Contact: Jesus Berdeja (principal investigator)
Fut, nem toboroz
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
NCT05723562· 2. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859· 3. fázis· Tesaro, Inc.· Forrás
Fut, nem toboroz
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633· 1. fázis· Tesaro, Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek